

Healthcare Professional Checklist

Timing	Activity	Detail
Initial screening of patients	Contraindications	<input type="checkbox"/> Hypersensitivity to the active substance or to any of the excipients <input type="checkbox"/> Human Immunodeficiency Virus (HIV) infection
	Recommended screening	<input type="checkbox"/> Evaluate for active and inactive ("latent") TB (per local guidelines) <input type="checkbox"/> Consider screening patients at high risk of HBV and/or HCV infection. Exercise caution in prescribing LEMTRADA to patients identified as carriers of HBV and/or HCV
	Baseline tests	<input type="checkbox"/> Complete Blood Count with differential <input type="checkbox"/> Serum creatinine <input type="checkbox"/> Thyroid function tests, such as TSH <input type="checkbox"/> Urinalysis with microscopy
	Understanding of Benefits & Risks	The patient has been informed about and understands the risks of serious autoimmune disorders, infections and malignancies, and the measures to minimise risk (e.g. watching for symptoms, carrying the Patient Alert Card and the need to commit to periodic monitoring for 48 months after the last treatment)
6 weeks prior to treatment <i>(if needed)</i>	Vaccinations	<input type="checkbox"/> It is recommended that patients have completed local immunisation requirements <input type="checkbox"/> Consider VZV vaccination of antibody negative patients before initiating a course of LEMTRADA treatment
Immediately prior to treatment	Pre-treatment <i>Pre-treatment for IARs</i> <i>Oral prophylaxis for herpes</i>	<input type="checkbox"/> Immediately prior to LEMTRADA pre-treat with corticosteroids on each of the first 3 days of any treatment course <input type="checkbox"/> Pretreatment with antihistamines and/or antipyretics prior to LEMTRADA administration may also be considered <input type="checkbox"/> Administer 200 mg aciclovir (or equivalent) twice a day from first day of treatment and continuing for a minimum of 1 month following treatment
	General health	<input type="checkbox"/> Consider delaying initiation of LEMTRADA administration in patients with active infection until the infection is fully controlled
	Pregnancy & contraception	<input type="checkbox"/> Ensure women of child bearing potential use effective contraceptive measures when receiving a course of treatment with LEMTRADA and for 4 months following the course of treatment <input type="checkbox"/> If patient is pregnant, administer only if the potential benefit justifies the potential risk to the foetus
During treatment and for 48 months after last treatment	Monitoring Activities	<input type="checkbox"/> Complete Blood Count w/Differential and Serum creatinine: Monthly until 48 months from last treatment <input type="checkbox"/> Urinalysis: Monthly until 48 months from last treatment <input type="checkbox"/> Thyroid function tests: Every 3 months until 48 months from last treatment

_____ on ____ / ____ / _____
 (Insert patient's name) (Insert date)

_____ ____ / ____ / _____
 (Insert patient's medical record number) (Insert patient date of birth)

 (Prescriber's name)